JP2007517016A5 - - Google Patents

Download PDF

Info

Publication number
JP2007517016A5
JP2007517016A5 JP2006546397A JP2006546397A JP2007517016A5 JP 2007517016 A5 JP2007517016 A5 JP 2007517016A5 JP 2006546397 A JP2006546397 A JP 2006546397A JP 2006546397 A JP2006546397 A JP 2006546397A JP 2007517016 A5 JP2007517016 A5 JP 2007517016A5
Authority
JP
Japan
Prior art keywords
drug
solid composition
composition according
particles
poloxamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006546397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517016A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/004287 external-priority patent/WO2005065657A2/en
Publication of JP2007517016A publication Critical patent/JP2007517016A/ja
Publication of JP2007517016A5 publication Critical patent/JP2007517016A5/ja
Abandoned legal-status Critical Current

Links

JP2006546397A 2003-12-31 2004-12-20 低溶解性薬剤及びポロキサマーの固体組成物 Abandoned JP2007517016A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53383603P 2003-12-31 2003-12-31
PCT/IB2004/004287 WO2005065657A2 (en) 2003-12-31 2004-12-20 Solid compositions of low-solubility drugs and poloxamers

Publications (2)

Publication Number Publication Date
JP2007517016A JP2007517016A (ja) 2007-06-28
JP2007517016A5 true JP2007517016A5 (cg-RX-API-DMAC7.html) 2008-02-14

Family

ID=34748969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006546397A Abandoned JP2007517016A (ja) 2003-12-31 2004-12-20 低溶解性薬剤及びポロキサマーの固体組成物

Country Status (6)

Country Link
US (1) US8974823B2 (cg-RX-API-DMAC7.html)
EP (1) EP1701704A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007517016A (cg-RX-API-DMAC7.html)
BR (1) BRPI0418330A (cg-RX-API-DMAC7.html)
CA (1) CA2548376A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005065657A2 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
EP2142178B1 (en) * 2007-03-29 2012-01-11 F. Hoffmann-La Roche AG Pharmaceutical composition and process
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
SMT202000390T1 (it) * 2010-07-12 2020-09-10 Salix Pharmaceuticals Inc Formulazioni di rifaximina e loro usi
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
JP2014532658A (ja) * 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ, インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
CN111700878A (zh) * 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CN105188371A (zh) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
JP5946798B2 (ja) * 2013-06-18 2016-07-06 住友ゴム工業株式会社 タイヤ用ゴム組成物、及び空気入りタイヤ
JP5934677B2 (ja) * 2013-06-18 2016-06-15 住友ゴム工業株式会社 タイヤ用ゴム組成物、及び空気入りタイヤ
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
JP6010060B2 (ja) * 2014-02-21 2016-10-19 住友ゴム工業株式会社 タイヤ用ゴム組成物、及び空気入りタイヤ
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
RU2639819C2 (ru) * 2014-12-30 2017-12-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Композиция, ингибирующая теломеразу
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
DK0996429T3 (da) 1997-10-27 2003-05-26 Merck Patent Gmbh Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler
AU4797999A (en) 1998-07-22 2000-02-14 Yamanouchi Pharmaceutical Co., Ltd. Solid preparation containing sparingly soluble nsaids
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
WO2001034118A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Solid dispersion pharmaceutical formulations
JP2004500358A (ja) 1999-12-08 2004-01-08 ファルマシア コーポレイション バイオアベイラビリティーが増加した固体状態のセレコキシブ
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
KR100806412B1 (ko) 2000-01-28 2008-02-21 스미스클라인 비참 코포레이션 전기방사 약제학적 조성물
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
PE20011184A1 (es) * 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US20010036959A1 (en) 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
AU2001257115B2 (en) 2000-04-20 2005-01-27 Rtp Pharma Inc. Improved water-insoluble drug particle process
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
GB0015239D0 (en) 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
DE10038571A1 (de) 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
KR20020014570A (ko) 2000-08-18 2002-02-25 김충섭 고체분산화시킨 무정형 이프리플라본의 제조방법
CZ20033211A3 (cs) * 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AU2003214387A1 (en) * 2002-03-07 2003-09-16 Biocompatibles Uk Limited Drug carriers comprising amphiphilic block copolymers

Similar Documents

Publication Publication Date Title
AU2005324132B2 (en) Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release
Khan et al. Formulation, characterisation and stabilisation of buccal films for paediatric drug delivery of omeprazole
ES2351947T3 (es) Formulaciones orales de liberacion controlada de un inhibidor de la enzima convertidora de interleucina-1-beta.
JP2011516612A5 (cg-RX-API-DMAC7.html)
MXPA02001243A (es) Medios para crear una masa que tiene integridad estructural.
JP2009502487A5 (cg-RX-API-DMAC7.html)
KR102663478B1 (ko) 에다라본 약제학적 조성물
JP6364406B2 (ja) 口腔内崩壊錠
DE60313359D1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
JP2013525394A (ja) 経口投与剤形
CN103550158B (zh) 一种大黄素固体分散体、含药丸芯和结肠靶向微丸及其用途
CN102548543B (zh) 具有改进的溶出率和最小的副作用的缓释的西洛他唑片剂
JP6838446B2 (ja) トルバプタン製剤およびその製造方法
CN100463674C (zh) 一种氯雷他定口腔速溶膜及其制备方法
Pinto et al. Cellulose ethers for extrusion applications
WO2025108447A1 (zh) 一种吲哚布芬缓释制剂及其制备方法和应用
CN107072954B (zh) 用于口服给药的包含洛贝格列酮的药物组合物
JP2002512946A5 (cg-RX-API-DMAC7.html)
CN110946835A (zh) 一种利伐沙班固体分散片及其制备方法
BR112014026040B1 (pt) Comprimido de liberação sustentada que contém levodropropizina
CN103505421B (zh) 一种盐酸度洛西汀的肠溶微丸制剂
CN104013582B (zh) 一种阿司匹林peg-plga微球的制备方法
JP6072705B2 (ja) 固体分散体製剤
CN104971052A (zh) 含有非马沙坦钾三水合物的药物组合物及其制备方法
CN102805738B (zh) 盐酸普罗帕酮缓释制剂及制备方法